PMID- 37772587
OWN - NLM
STAT- MEDLINE
DCOM- 20231002
LR  - 20231002
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 10
DP  - 2023 Oct
TI  - Clinical Outcomes With Lenvatinib in Patients Previously Treated With 
      Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.
PG  - 4673-4682
LID - 10.21873/anticanres.16663 [doi]
AB  - BACKGROUND/AIM: The combination of atezolizumab plus bevacizumab (Atz/Bev) has 
      become widely used as a first-line therapy for advanced hepatocellular carcinoma 
      (HCC). However, for post-Atz/Bev therapy, evidence on the outcomes of molecular 
      targeted agents, such as lenvatinib, is limited. The present study aimed to 
      assess the clinical effectiveness of lenvatinib on advanced HCC in patients who 
      had previously undergone Atz/Bev treatment. PATIENTS AND METHODS: Twenty patients 
      with HCC, who received lenvatinib after Atz/Bev treatment, were enrolled in the 
      study. In particular, we examined the impact of adverse events (AEs), such as 
      anorexia and general fatigue. During the treatment, lenvatinib dosages were 
      adjusted or temporarily discontinued in response to AEs. Treatment outcomes were 
      retrospectively evaluated. RESULTS: The objective response rate (ORR) and disease 
      control rate (DCR) for lenvatinib treatment were 25.0% and 95.0%, respectively, 
      according to the Response Evaluation Criteria in Solid Tumors. The median 
      progression-free survival (PFS) was 6.0 months, and the median overall survival 
      (OS) was 10.5 months. Eleven patients experienced anorexia or fatigue, leading to 
      a reduction in the dose of lenvatinib but not to a significant difference in the 
      time to drug discontinuation. Importantly, there were no significant differences 
      between the 11 anorexia/fatigue-suffering patients and the nine other patients 
      with regard to PFS and OS. CONCLUSION: Lenvatinib can be efficacious and safe for 
      treating advanced HCC patients previously treated with Atz/Bev, and AEs such as 
      anorexia and general fatigue can be effectively managed without losing 
      lenvatinib's therapeutic benefits.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Muto, Hisanori
AU  - Muto H
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
AD  - Department of Gastroenterology and Hepatology, Fujita Health University Bantane 
      Hospital, Nagoya, Japan.
FAU - Kuzuya, Teiji
AU  - Kuzuya T
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan; teiji.kuzuya@fujita-hu.ac.jp.
FAU - Kawabe, Naoto
AU  - Kawabe N
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Ohno, Eizaburo
AU  - Ohno E
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Funasaka, Kohei
AU  - Funasaka K
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Nagasaka, Mitsuo
AU  - Nagasaka M
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Nakagawa, Yoshihito
AU  - Nakagawa Y
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Miyahara, Ryoji
AU  - Miyahara R
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Shibata, Tomoyuki
AU  - Shibata T
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Hashimoto, Senju
AU  - Hashimoto S
AD  - Department of Gastroenterology and Hepatology, Fujita Health University Bantane 
      Hospital, Nagoya, Japan.
FAU - Katano, Yoshiaki
AU  - Katano Y
AD  - Department of Gastroenterology and Hepatology, Fujita Health University Bantane 
      Hospital, Nagoya, Japan.
FAU - Hirooka, Yoshiki
AU  - Hirooka Y
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 52CMI0WC3Y (atezolizumab)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Humans
MH  - Anorexia
MH  - Bevacizumab/therapeutic use
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Fatigue/chemically induced
MH  - *Liver Neoplasms/drug therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Atezolizumab/bevacizumab
OT  - adverse event
OT  - anorexia
OT  - general fatigue
OT  - hepatocellular carcinoma
OT  - lenvatinib
OT  - liver function
OT  - post-progression treatment
EDAT- 2023/09/29 12:43
MHDA- 2023/10/02 06:42
CRDT- 2023/09/29 07:31
PHST- 2023/07/30 00:00 [received]
PHST- 2023/09/04 00:00 [revised]
PHST- 2023/09/05 00:00 [accepted]
PHST- 2023/10/02 06:42 [medline]
PHST- 2023/09/29 12:43 [pubmed]
PHST- 2023/09/29 07:31 [entrez]
AID - 43/10/4673 [pii]
AID - 10.21873/anticanres.16663 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 Oct;43(10):4673-4682. doi: 10.21873/anticanres.16663.